Skip to main content
OpenTrials
Completed

NCT Number: NCT00949845

Cytokine-Associated Depression and Social Pain

Recent research has demonstrated a relationship between depression and immune system activity, specifically proinflammatory cytokine activity. Although experimentally-induced immune activation leads to increases in depressed mood, the neural correlates associated with these changes have remained largely unexplored. Based on relationships between cytokine activity, depression, and heightened physical and social pain sensitivity, I propose to investigate the effect of proinflammatory cytokine activation on the neural correlates of socially painful experience that may contribute to depression. Our previous work has shown that the dorsal anterior cingulate cortex (dACC), typically associated with physical pain distress, also plays a role in the distressing feelings associated with social rejection or social loss. Moreover, recent pilot data has revealed that individuals with elevated levels of baseline proinflammatory cytokines report feeling more distressed and show more dACC activity during social rejection. To investigate the causal role that cytokines may play in the heightened social pain sensitivity that can contribute to depression, participants will be randomly assigned to receive either endotoxin (which increases proinflammatory cytokine activity) or placebo. Subsequently, participants will complete a neuroimaging study in which they will be rejected during an online ball-tossing game. We hypothesize that individuals exposed to endotoxin will report more social distress and depression following rejection and will show more dACC reactivity during rejection. The proposed study is the first to investigate the effect of systemic inflammation on neural reactivity related to social and affective processes that may increase the risk of depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

UCLA General Clinical Research Center

Los Angeles, California, 90095, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • right-handed

Exclusion criteria

  • 1) BMI greater than 30,
  • 2) presence of physical health problems or medication use,
  • 3) evidence of an Axis I psychiatric disorder based on the SCID assessment,
  • 4) evidence of recreational drug use from a positive urine test,
  • 5) positive pregnancy test, if female,
  • 6) abnormalities on screening laboratory tests (blood cell count, liver function),
  • 7) claustrophobia,
  • 8) metal in body,
  • 9) history of allergies, autoimmune, liver, or other severe chronic diseases,
  • 10) current use of prescription medications,
  • 11) nightshift work or time zone shifts (> 3hrs) within the previous 6 weeks.

Treatment and study plan

Endotoxin

Drug

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Official study title

An fMRI Study of Cytokine-Associated Depression and Social Pain

Important dates

Study start
2007
First posted
Jul 30, 2009
Registry last updated
Jul 30, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.